Skip to Content

DTPA (pentetic acid) Disease Interactions

There are 2 disease interactions with DTPA (pentetic acid):


Pentetic acid (applies to DTPA) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The image quality obtained with Technetium Tc 99m pentetate may be adversely affected by impaired renal function. Literature reports indicate that the target to non-target ratio for intracranial lesions may take several hours to develop fully, thus the possibility of missing certain lesions when imaging is restricted to the early period after injection should be recognized.


Technetium Tc 99m bicisate/exametazime/pentetate (applies to DTPA) renal dysfunction

Moderate Potential Hazard, High plausibility.

Technetium Tc 99m conjugates (e.g., bicisate, exametazime, pentetate) are often eliminated by the kidney, and the risk of toxic reactions to these drugs may be greater in patients with impaired renal function. Dosage adjustments have not been studied in patients with renal and/or hepatic impairment. Caution is advised when used in these patients.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.